Drug Trial Radar · NCT06911333
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Jun 30, 2029
Study completion Feb 20, 2030
Sponsor
- Lead sponsor
- Avelos Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug
Conditions
- Solid Tumor, Adult
- Tumor, Solid
- Solid Tumor
- Solid Tumor, Unspecified, Adult
- Solid Tumor Cancer
- Solid Tumors Refractory to Standard Therapy
- Solid Tumor in Advanced Stage
Interventions
AD1208Drug
Up to 6 of cohorts will be applied sequentially in phase Ia part.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: At the end of Cycle 1 (each cycle is 21 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.